Global Blood Therapeutics And Crispr – Which Firm Will Capture The Lucrative Hemoglobinopathy Market? – Seeking Alpha
|
Global Blood Therapeutics And Crispr – Which Firm Will Capture The Lucrative Hemoglobinopathy Market?
Seeking Alpha Voxelotor demonstrates robust data thus far to potentially position it for capturing the lucrative sickle cell disease (“SCD”) market. Lead drug CTX-001 of Crispr Therapeutics works by a different mechanism of action and likely to complement Voxelotor … |
